Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
PIGY pseudogene 1 (PIGYP1) is presumed to be a nonfunctional genomic DNA sequence resembling the protein-coding gene PIGY (Phosphatidylinositol glycan anchor biosynthesis class Y). Pseudogenes such as this typically arise through gene duplication or retrotransposition events, and although they may be transcribed, they generally do not encode functional proteins or act as drug targets. There is no established evidence that "PIGY pseudogene 1" serves as a therapeutic target or is involved in recognized molecular pathways or diseases. Its presence in a database may reflect ongoing pseudogene annotation rather than functional characterization[2][4][7].\n\nKey Notes:\n- "PIGY" refers to an enzyme component of the GPI-anchor biosynthesis pathway, important for cell surface protein anchoring[4], but "PIGY pseudogene 1" is not functionally established.\n- Pseudogenes are not standard therapeutic targets and typically lack roles in direct drug interaction or disease intervention[2][7].\n- Return null or flag this entry as noncanonical/incorrect for purposes where only established protein-coding drug targets are considered.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on PIGY pseudogene 1 (PIGYP1).